FDA
-
-
-
-
-
-
-
Insulet rolls out enhanced Omnipod 5 algorithm with Abbott sensor compatibility
-
-
-
-
-
-
-
INSULET recalls specific Omnipod 5 pods due to insulin leak risk
-
-
-
-
-
-
-
Insulet Announces FDA 510(k) Clearance of Omnipod® 5 Algorithm Enhancements that Redefine Insulin Delivery and Simplify the Pod Experience
-
-
-
-
-
-
-
Insulet Reports First Quarter 2025 Revenue Increase of 29% Year-Over-Year (30% Constant Currency¹)
-
-
-
-
-
-
-
Insulet Corporation (PODD) PT Raised to $234 at Barclays
-
-
-
-
-
-
-
Omnipod® 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes
-
-
-
-
-
-
-
Insulet Reports Full Year 2023 Revenue Increase of 30% (30% Constant Currency¹) and Fourth Quarter 2023 Revenue Increase of 38% Year-Over-Year (37% Constant Currency)
-
330,617 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

